Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans

What Was Tested

The paper reports a study of Ghrelin, published as a randomized controlled trial.

This study aimed to investigate plasma ghrelin levels during human bacterial endotoxemia.

Why It Was Studied

Ghrelin is a gut hormone with a highly preserved biological activity, which seems not to be restricted to the regulation of food intake, body composition, and growth.

Continuous research is unraveling new properties of ghrelin, among others cardiovascular and antiinflammatory activities.

Who Took Part

The abstract describes 10 men taking part.

By PubMed's age tags, the people studied were adults, men only.

Participants included 10 healthy men.

How the Study Was Run

The design is described as randomized, placebo-controlled and crossover.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some men received a placebo instead of Ghrelin, giving a reference point.

Each person switched between Ghrelin and the comparison at some point, usually with a gap in between.

The researchers conducted a randomized, placebocontrolled, crossover clinical trial at a university medical center.

What Was Measured

Topics PubMed links to this paper include Cytokines, Endotoxemia, Ghrelin, Inflammation, Lipopolysaccharides, Neurosecretory Systems and Sepsis.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Ghrelin in 10 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Ghrelin compound page, all human trials.